Midterm Follow-up of Balloon-Expandable ePTFE Endografts in the Femoropopliteal Segment

Purpose: To evaluate the midterm clinical outcome of patients treated with a balloon-expandable polytetrafluoroethylene (ePTFE) endograft for long-segment occlusive disease of the femoropopliteal segment. Methods: Eighty-nine patients (68 men; median age 69 years, range 43–81) with disabling claudic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endovascular therapy 2002-08, Vol.9 (4), p.428-435
Main Authors: Hagenaars, Tjebbe, Gussenhoven, Elma J., Smeets, Luuk, Moll, Frans L., Buth, Jacob, Nevelsteen, Andre, van Dijk, Lukas C., van Sambeek, Marc R.H.M., van Urk, Hero
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Arterial Occlusive Diseases - surgery
Blood Vessel Prosthesis Implantation
Female
Femoral Artery - surgery
Follow-Up Studies
Humans
Male
Middle Aged
Polytetrafluoroethylene - therapeutic use
Popliteal Artery - surgery
Treatment Outcome
Vascular Patency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: To evaluate the midterm clinical outcome of patients treated with a balloon-expandable polytetrafluoroethylene (ePTFE) endograft for long-segment occlusive disease of the femoropopliteal segment. Methods: Eighty-nine patients (68 men; median age 69 years, range 43–81) with disabling claudication (n=73) or critical ischemia (n=16) were treated with an ePTFE endograft (mean length 29 cm) for 7 stenosis (mean length 9 cm) and 82 occlusions (mean length 19 cm) in the femoropopliteal segment. The follow-up protocol included Doppler ankle-brachial pressure measurement and duplex scanning or angiography of the endograft at 6-month intervals. Primary and secondary patency rates were analyzed. Results: At the last examination, the endograft was patent in 52 patients (median 17 months, range 7–50) and occluded in 35 (median 7 months, range 0–40);2 patients died of nonvascular causes with a patent endograft at 6.5 and 7 months. At follow-up, the primary and secondary endograft patency rates were 71% and 83% at 6 months, 57% and 69% at 1 year, 45% and 49% at 2 years, and 30% and 44% at 3 years, respectively. Conclusions: The midterm success of this new ePTFE endograft is limited; therefore, the device needs to be refined if this minimally invasive technique is to compete with conventional bypass surgery.
ISSN:1526-6028
1545-1550
DOI:10.1177/152660280200900408